Sugi Predict

Sugi Predict / Compounds / SCHEMBL891636

SCHEMBL891636

SCHEMBL891636

C[C@H](O)c1c(Cl)cncc1Cl

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.39
▸ CYP11B2 P19099 3/20 0.39
▸ USP7 Q93009 1/20 0.36
▸ RECQL P46063 1/20 0.34
▸ PDE4B Q07343 4/20 0.31
▸ PDE4A P27815 2/20 0.31
▸ PDE4C Q08493 2/20 0.31
▸ PDE4D Q08499 2/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ MAPK3 P27361 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288954 1.00 MAPT (0.39) MAPTCYP11B2USP7RECQLPDE4B
SCHEMBL22814329 1.00 MAPT (0.39) MAPTCYP11B2USP7RECQLPDE4B
SCHEMBL18884152 0.87 CYP11B2 (0.36) MAPTCYP11B2USP7RECQL
SCHEMBL18393034 0.85 CYP11B2 (0.50) MAPTCYP11B2USP7RECQLPDE2A
SCHEMBL1769870 0.85 CYP11B2 (0.35) MAPTCYP11B2USP7RECQL
SCHEMBL30708125 0.84 MAPT (0.33) MAPTCYP11B2USP7
SCHEMBL20604443 0.81 APLNR (0.39) MAPTCYP11B2USP7PDE4BPDE4A
SCHEMBL20604447 0.81 APLNR (0.39) MAPTCYP11B2USP7PDE4BPDE4A
SCHEMBL84898 0.79 MAPT (0.37) MAPTGAA
SCHEMBL18572976 0.75 CYP11B2 (0.33) CYP11B2USP7PDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 — — US disclosed
CN-119731165-A Indazole compounds 泰拉生物科学公司 2025-03-28 — — CN disclosed
EP-4186894-B1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-12-04 — — EP disclosed
WO-2024137742-A1 COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-06-27 — — WO disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
EP-4186894-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2023-05-31 — — EP disclosed
EP-3919477-A1 FLUOROVINYLBENZAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR Medshine Discovery Inc. (CN) 2021-12-08 — — EP disclosed
EP-3919478-A1 VINYLPYRIDINE CARBOXAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR Medshine Discovery Inc. (CN) 2021-12-08 — — EP disclosed
CN-113666911-A FGFR inhibitor compounds and uses thereof 河南迈英诺医药科技有限公司 2021-11-19 — — CN disclosed
WO-2021138391-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES, INC. (US) 2021-07-08 — — WO disclosed
CN-102421769-B Vinyl indazolyl compounds LILLY CO ELI (US) 2014-04-02 — — CN disclosed
US-8530665-B2 Crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol ELI LILLY AND COMPANY (US) 2013-09-10 — — US disclosed
EP-2625175-A1 CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR Eli Lilly and Company (US) 2013-08-14 — — EP disclosed
CN-103153983-A Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor LILLY CO ELI 2013-06-12 — — CN disclosed
EP-2427449-B1 VINYL INDAZOLYL COMPOUNDS LILLY CO ELI (US) 2013-04-03 — — EP disclosed
US-8268869-B2 Vinyl indazolyl compounds ELI LILLY AND COMPANY (US) 2012-09-18 — — US disclosed
CN-102421769-A Vinyl indazolyl compounds LILLY CO ELI (US) 2012-04-18 — — CN disclosed
WO-2012047699-A1 CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR ELI LILLY AND COMPANY (US) 2012-04-12 — — WO disclosed
US-20120083511-A1 CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL ELI LILLY AND COMPANY (US) 2012-04-05 — — US disclosed
US-20100286209-A1 VINYL INDAZOLYL COMPOUNDS ELI LILLY AND COMPANY 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630530-B2 FGFR inhibitor compound and use thereof FGFR3, FGFR1, FGFR4 MAPT 2238/4885CYP11B2 423/4885USP7 3700/4885
US-20120083511-A1 CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL ADH1A, ADH1C, ADH5 MAPT 2271/4885CYP11B2 3764/4885USP7 4107/4885
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF FGFR3, FGFR1, FGFR4 MAPT 366/4885CYP11B2 250/4885USP7 4634/4885
US-20100286209-A1 VINYL INDAZOLYL COMPOUNDS VHL, IDH3B, IDH3A MAPT 3942/4885CYP11B2 1183/4885USP7 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.